Publications by authors named "A Vossos"
Purpose: To assess the efficacy and tolerance of the vinorelbine/cisplatin combination in non-small cell lung cancer patients pre-treated with a taxane-based regimen.
Patients And Methods: Among the 32 enrolled patients, 28 (87.5%) had a PS (WHO) of 0-1 and 13 (40.
Purpose: To evaluate the efficacy and tolerance of the irinotecan plus docetaxel combination in patients with advanced non-small cell lung cancer (NSCLC).
Patients And Methods: Thirty-nine chemotherapy-naïve patients with advanced NSCLC were treated with irinotecan 200mg/m2 followed by docetaxel 80 mg/m2 intravenously on day 1 with granulocyte colony-stimulating factor (150 microg/m2) support from day 2 to 9. Treatment was repeated every 3 weeks.
Article Synopsis
- The study aimed to evaluate docetaxel's efficacy, supported by G-CSF, in patients with advanced non-small-cell lung cancer (NSCLC) who previously received cisplatin treatment.
- Out of 60 patients, the overall response rate to docetaxel was 25%, with 1.6% achieving a complete response and 23.3% a partial response; median overall survival was 32 weeks.
- Docetaxel showed significant activity as a standalone treatment, though some patients experienced severe side effects like neutropenia and peripheral neuropathy.
Purpose: To evaluate the efficacy and safety of the docetaxel-cisplatin combination in patients with advanced non-small-cell lung cancer (NSCLC).
Patients And Methods: Chemotherapy-naïve patients with histologically confirmed, measurable stage IIIB or IV NSCLC, a World Health Organization (WHO) performance status of 0-2 and adequate bone marrow, renal, hepatic and cardiac function were eligible for the study. Patients received docetaxel (100 mg/m2) as an one-hour infusion on day 1 and cisplatin (80 mg/m2) as a 30-min infusion with appropriate hydration on day 2.